Current drug development strategies are very expensive and lead to high drug attrition rates.

Read how we can help

Cardiovascular Drug Efficacy Services

Current drug development strategies are very expensive and lead to high drug attrition rates. One major reason for low success rates is the lack of predictive preclinical models for efficacy (and safety) testing. At Ncardia we combine our cardiovascular knowledge with expertise on hiPSC-derived cardiomyocyte manufacturing to offer you predictive and translational in vitro disease models, and assays for efficacy screening at any throughput.


Why you should work with us for our drug efficacy studies:

Cardiovascular expertise - make use of our knowledge
Results you can trust - guaranteed by the reproducible and translatable production of hiPSC-derived cells
Save time and money - make use of our state-of-the-art technologies and equipment
Customized approach - our goal is to meet your objectives

Disease modeling
Assay development
High Throughput Screening

Disease modeling

Preclinical efficacy studies are commonly conducted by utilizing animal models, and primary cells or immortalized cell lines. However, all these models have shortcomings, which can negatively impact the predictivity of such studies.

With the discovery of human induced pluripotent stem cell (hiPSC) technologies, we can now generate virtually any human cell type from hiPSCs. This makes the technology an ideal tool for efficacy screening studies which require human cell-based models that exhibit the disease phenotype.

At Ncardia we are specialized in the generation of hiPSC-derived cardiomyocytes. Our proprietary differentiation protocol of Pluricyte® Cardiomyocytes is serum-free and easily scalable, providing a relatively mature cardiomyocyte model without genetic modifications, with high predictivity in cardiac toxicity and efficacy assays. Based on this proprietary technology, high-quality (diseased) cardiomyocytes can be generated from any individual with any genetic, ethnic or disease background. Alternatively, our healthy hiPSC-derived cardiomyocytes can be modified through addition of cytokines, hormones, chemicals or other ligands to the culture medium, or by the use of genetic technologies. In combination with specialized assay development experience, we can generate highly relevant “disease in a dish” models for efficacy studies. For more detailed and mechanistic investigations (for improved translation to in vivo, for instance), more complex in vitro techniques like 3D cultures, co-cultures with other cell types, and/or mimicking of a physiologically-relevant environment of the cells can be applied to create “organ-on-a-chip” models. Just let us know which features you require in the model and we can discuss together the possibilities.

Cell manufacturing

To implement hiPSC-derived cardiomyocytes in every stage of drug discovery and development, manufacturing of large batches of human cardiomyocytes with low batch-to-batch variation is key.

At Ncardia we employ state-of-the-art bioreactor systems for the cultivation of high quality hiPSC-derived cardiomyocytes. The combination of these systems with our proprietary differentiation protocols allows us to offer a fast and robust industrial-scale manufacturing of the hiPSC-derived cells of interest.

Assay development

For successful efficacy studies, predictive and validated in vitro assays are needed to test the effect of drug candidates in your hiPSC-derived disease model.

We can apply disease models in a range of validated contractility- , biochemistry- and electrophysiology-based assays to support your efficacy screening activities. In addition, our dedicated assay development scientists can develop new assays to investigate the specific phenotype you are interested in. As such, we can provide the optimal combination of cell-type and phenotypic assay to meet your specific needs.

High Throughput Screening

Our in-house automation platforms in combination with Pivot Park Screening Centre’s ultra-High Throughput Screening (uHTS) facilities enable phenotypic screening at any throughput.

To facilitate screening projects, we have access to a library of 300,000 high quality drug-like compounds. At the screening centre we have experience with handling compound libraries up to 2.5 million compounds. In combination with novel HTS-ready assays and high quality disease models, we can perform relevant and efficient drug efficacy screens.


Do you have questions about our drug efficacy studies using hiPSC-derived disease models? Our experts are here to help - contact us now!